3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
4
Active not recruiting
4
Completed
2
Sponsor Class
NETWORK
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
1
Breast
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
pembrolizumab
27
Cisplatin
17
Nivolumab
14
Cyclophosphamide
14
Carboplatin
13
Radiation
12
Paclitaxel
12
Doxorubicin
11
Radiotherapy
10
Radiotherapy, Intensity-Modulated
9
Cytarabine
9
Vincristine
8
Magnetic Resonance Spectroscopy
8
Docetaxel
8
Bevacizumab
8
Radiosurgery
7
Leucovorin
7
Fluorouracil
7
Etoposide
7
Specimen Handling
6
Prednisone
6
Pemetrexed
6
Irinotecan
6
Injections
6
Gemcitabine
6
Dexamethasone
6
venetoclax
5
tislelizumab
5
fludarabine
5
enzalutamide
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
trifluridine tipiracil drug combination
×
30 days
×
Clear all
NCT05064059
2026-05-26
MK-4280A-007
Merck Sharp & Dohme LLC
Phase 3
Completed
441 enrolled
24 charts
NCT04489173
2026-05-22
TIBET
Borstkanker Onderzoek Groep
Phase 2
Completed
52 enrolled